Lakefront Biotherapeutics (LKFT) Convertible Debt (2025 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Convertible Debt of $24.6 million for Q1 2026, up 1.89% on a QoQ basis from $24.1 million in Q4 2025.
Lakefront Biotherapeutics (LKFT) Convertible Debt (2025 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Convertible Debt for 2 consecutive years, with $24.6 million the latest figure, recorded in Q1 2026.
- Quarterly Convertible Debt changed N/A year-over-year to $24.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.6 million (changed N/A YoY) and the FY2025 annual result came in at $24.1 million, changed N/A from the prior year.
- Convertible Debt improved to $24.6 million in Q1 2026 per LKFT's latest filing, from $24.1 million in the prior quarter.
- Over the last five years, Convertible Debt for LKFT reached as high as $24.6 million in Q1 2026 and fell as low as $23.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Lakefront Biotherapeutics | 1.85 Bn | -1.64 Bn | 1.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24.55 Mn |
| Dec 31, 2025 | 24.10 Mn |
| Sep 30, 2025 | 23.63 Mn |
| Jun 30, 2025 | 23.16 Mn |